Some stakeholders are questioning the usefulness of the unified agenda in mapping out what regulatory actions FDA plans to take in the next 12 months, despite the White House’s claims that it has taken steps to make the semi-annual regulatory plan more useful to stakeholders. An investigation by Inside Health Policy found regulations pulled by FDA have ended up resurfacing as new efforts, and the agency itself insists an item's removal from the agenda doesn't necessarily mean work has...